Current Strategies and Approaches in Combating SARS-CoV-2 Virus that Causes COVID-19

Author(s): D. Sivaraman*, P. S. Pradeep, S. Sundar Manoharan, C. Ramachandra Bhat, K. V. Leela, V. Venugopal

Journal Name: Letters in Drug Design & Discovery

Volume 17 , Issue 5 , 2020

Become EABM
Become Reviewer

Abstract:

The pandemic spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2) that causes COVID-19 calls for global health emergency with wide prevalence across 94 countries, and around 3073 deaths reported in china on 7th March 2020 which created red alert zone in the country. It was further noticed other than China, countries like the republic of Korea ranked first with 6767 cases, Italy with 4747 and Iran with 3513 cases. The spread of COVID-19 made a historical transition between December 2019 to March 2020 by extending the paradigm to a newer territory every day with the highest predicted reproductive number <2. Hence, while combating the epidemic spread, there are spectra of strategies that require crucial validation, some of which include drug repurposing, enzyme inhibition, target drug delivery etc. Among these, the category of drugs called enzyme inhibitors has a unique opportunity in the process of new drug discovery as these enzymes possess structural versatility starting from the host viral interface and up to the release of a new virus. Drugs entrapped within liposomes are highly effective against intracellular microorganisms as per published observations. Regulatory authorities like World Health Organization (WHO) and Centre for disease control and prevention (CDC) strongly recommend the need for the PPE’s like N95 respirator to avoid person to person contact. In this context, Electrospun Nanofiber Technology (ENT) offers ultrathin fibres (20-200 nm) with close proximity of 99.97% of high efficient air filtration. Fabrication of ultrafine nano mask by utilizing electospun technology will surely benefit millions of people in a time-dependent manner.

Keywords: SARS-CoV-2, COVID-19, enzyme inhibitors, liposomes, electrospun nanofiber technology, nano mask.

[1]
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020, 395, 497-506.
[2]
Anthony, R.; Fehr, S.P. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol., 2015, 1282, 1-23.
[3]
Li, W.H.; Moore, M.J.; Vasilieva, N.; Sui, J.H. Angiotensin -converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426, 450-454.
[4]
Raj, V.S.; Mou, H.H.; Smits, S.L.; Dekkers, D.H.W. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus -EMC. Nature, 2013, 495, 251-254.
[5]
Zumla, A.; Chan, J.; Azhar, E.I.; Hui, D.S. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov., 2016, 15, 327-347.
[6]
Guangdi, Li.; Erik, D.C. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov., 2020, 19, 149-150.
[7]
Andres, P.; Blandine, P.; Olivier, T. Drug repurposing approaches for the treatment of influenza viral infection = reviving old drugs to fight against a long-lived enemy. Front. Immunol., 2019, 10, 531.
[8]
Pradeep, P.S.; Nellore, J.; Balaraman, R.M.; Sekar, U. Novel pyochelin-based PEGylated liposomes for enhanced delivery of antibiotics against resistant clinical isolates of Pseudomonas aeruginosa. Artif. Cells Nanomed. Biotechnol., 2018, 46, 2043-2053.
[9]
Omri, A.; Beaulac, C.; Bouhajib, M.; Montplaisir, S. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 1994, 38, 1090-1095.
[10]
U.S. Food and Drug administration. Masks and N95 Respirators. Personal protective equipment for infection and control 2020. Available at: https=// www.fda.gov/medical-devices/personal-protective-equipment-infection-control/masks-and-n95-respirators [Accessed: March 7, 2020].
[11]
Mei, Yu.; Michael, L. Crystal Structure of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein Dimerization Domain Reveals Evolutionary Linkage between Corona- and Arteriviridae. J. Biol. Chem., 2006, 281, 17134-17139.
[12]
Bałazy, A.; Do Toivola, M. N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks? Am. J. Infect. Control, 2006, 34, 51-57.
[13]
Shu, A.L.; Sergey, A. Grinshpun. Respiratory performance offered by N95 respirators and surgical masks= human subject evaluation with NaCl aerosol representing bacterial and viral particle size range. Ann. Occup. Hyg., 2008, 52, 177-185.
[14]
Kathryn, A.W.; Vinod, B.D. Fabrication of biodegradable polymeric nanofibers with covalently attached NO donors. ACS Appl. Mater. Interfaces, 2012, 4, 3022-3030.
[15]
Jiajia, X. Electrospinning and electrospun nanofibers= methods, materials, and applications. Chem. Rev., 2019, 119, 5298-5415.
[16]
Hirenkumar, K.M. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel), 2011, 3, 1377-1397.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 5
Year: 2020
Page: [672 - 674]
Pages: 3
DOI: 10.2174/157018081705200403092546

Article Metrics

PDF: 27
HTML: 2